Mounjaro Side Effects: What to Expect With Tirzepatide
If nausea, constipation, diarrhea, or vomiting starts after a tirzepatide injection, it does not automatically mean the medication is unsafe for you. Gastrointestinal side effects are among the most frequently reported problems with tirzepatide, and nausea, vomiting, and diarrhea tend to occur more often while the dose is being increased.
There is an important U.S. labeling distinction. Mounjaro and Zepbound contain the same active ingredient, tirzepatide, but Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management in eligible adults. For that reason, the weight-management side-effect rates below come from Zepbound clinical trials.
How Common Are Tirzepatide Side Effects?
In two pooled weight-management trials, gastrointestinal adverse reactions occurred in 56% of participants taking Zepbound at 5 mg, 10 mg, or 15 mg, compared with 30% taking placebo.
The most commonly reported individual side effects were:
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Indigestion | 4% | 9% | 9% | 10% |
| Injection-site reactions | 2% | 6% | 8% | 8% |
| Hair loss | 1% | 5% | 4% | 5% |
These numbers also show that every side effect does not automatically become more frequent as the dose increases. For example, constipation was reported more often with 5 mg than with 15 mg in these trials.
Why Side Effects May Feel Worse After a Dose Increase
Tirzepatide dosing is increased gradually in part to reduce gastrointestinal side effects. For Zepbound, treatment starts at 2.5 mg once weekly for four weeks, followed by 5 mg. Further increases are made in 2.5 mg steps after at least four weeks at the current dose when appropriate.
In the weight-management trials, most nausea, vomiting, and diarrhea occurred during dose escalation and decreased over time. This does not mean everyone will improve automatically, however.
Contact your prescriber if symptoms are severe, continue without improving, or make it difficult to eat or drink. Do not increase, decrease, or stop a prescription dose on your own.
What Can You Eat When Tirzepatide Upsets Your Stomach?
When nausea is mild, eating less at one time may be easier than trying to finish a regular-size meal. Smaller meals, stopping when you feel full, avoiding fatty foods, and choosing bland foods such as toast, crackers, or rice may help.
If you have diarrhea or vomiting, preventing dehydration becomes especially important. Sip water or other clear fluids throughout the day rather than trying to drink a large amount all at once. Persistent vomiting or diarrhea deserves medical attention because fluid loss can contribute to kidney problems.
For constipation, gradually increasing fiber from fruits, vegetables, beans, and whole grains, drinking enough fluids, and staying physically active may help. Adding a large amount of fiber suddenly can worsen gas or bloating, and fiber without enough fluid may make constipation worse.
People who have heart failure, kidney disease, or another condition that requires fluid restriction should ask their healthcare provider how much fluid is appropriate rather than simply increasing intake.
When Do Tirzepatide Side Effects Need Medical Care?
Some symptoms should not be treated as routine stomach upset.
Persistent or severe abdominal pain, especially if it spreads toward the back and occurs with or without nausea or vomiting, can be a symptom of acute pancreatitis and needs prompt medical evaluation. In pooled Zepbound weight-management trials, adjudicated acute pancreatitis occurred in 0.2% of both the tirzepatide and placebo groups.
Contact a healthcare professional promptly for persistent nausea, vomiting, or diarrhea, particularly if you cannot keep fluids down or develop symptoms suggesting dehydration.
Seek immediate medical care for symptoms of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat or difficulty breathing or swallowing. Tirzepatide labeling also includes warnings for gallbladder disease, severe gastrointestinal problems, and acute kidney injury related to volume depletion.
Postmarketing reports have also included ileus, intestinal obstruction, and severe constipation. Severe abdominal swelling with repeated vomiting or an inability to pass stool or gas should not be managed as ordinary constipation at home.
What Should Your Healthcare Team Know Before Your Next Dose?
If you use insulin or a sulfonylurea for type 2 diabetes, tirzepatide can increase the risk of hypoglycemia when these medications are used together. Your healthcare provider may need to review your diabetes treatment and glucose readings.
Tell your surgical, anesthesia, or endoscopy team that you take tirzepatide before any procedure involving general anesthesia or deep sedation. Tirzepatide delays stomach emptying, and rare cases of pulmonary aspiration have been reported during these procedures. Current labeling states that available evidence is not sufficient to establish one universal strategy for temporarily stopping the medication before a procedure, so follow the instructions of the clinicians managing your procedure.
People using oral hormonal birth control should also know that tirzepatide can reduce its effectiveness. U.S. labeling advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase.
Tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The boxed warning is based on thyroid C-cell tumors found in rats; whether tirzepatide causes these tumors in humans has not been established.
Mild Side Effects and Warning Symptoms Should Be Treated Differently
Mild nausea, diarrhea, constipation, or stomach discomfort can sometimes be managed with smaller meals, appropriate hydration, and food adjustments while your body adapts to treatment.
But being unable to eat or drink normally, persistent vomiting, severe abdominal pain, significant abdominal swelling, breathing difficulty, or symptoms of dehydration are reasons to contact a healthcare professional rather than simply waiting for the next injection.
Knowing what is expected during dose escalation—and what falls outside the usual pattern—can make tirzepatide treatment safer and easier to discuss with your prescriber.
Source:
U.S. National Library of Medicine, DailyMed — Zepbound (tirzepatide) Prescribing Information
U.S. National Library of Medicine, DailyMed — Mounjaro (tirzepatide) Prescribing Information
MedlinePlus — Tirzepatide Injection Drug Information; Nausea and Vomiting; Constipation Self-Care
Eli Lilly and Company — Zepbound Side Effect Management Information
